...A) 6/14/19 $15.0 NA $5.7 NA Seres Therapeutics Inc. (NASDAQ:MCRB) 6/13/19 $60.0 $152.5 $218.2 43% Navidea Biopharmaceuticals Inc....

...managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc....
...become CEO of the immunotherapy company's Macrophage Therapeutics Inc. subsidiary. During a conference call Thursday, Navidea...
...pipeline and addressing its long-term funding needs. CFO and COO Jed Latkin will serve as Navidea's...

...were not disclosed. Navidea obtained exclusive, worldwide rights to NAV4694 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Navidea Biopharmaceuticals Inc....
...Tel Aviv:NAVB), Dublin, Ohio Cerveau Technologies Inc., Boston, Mass. Business: Diagnostic Allison Johnson NAV4694, azd4694 AstraZeneca plc Cerveau Technologies Inc. Navidea Biopharmaceuticals Inc....

...Norgine B.V. (Amsterdam, the Netherlands) has exclusive commercialization rights (see BioCentury, March 9, 2015 ). Navidea Biopharmaceuticals Inc....
...NYSE-M:NAVB; Tel Aviv:NAVB), Dublin, Ohio Cardinal Health Inc. (NYSE:CAH), Dublin, Ohio Business: Diagnostic Alex Himes Lymphoseek Cardinal Health Inc. Navidea Biopharmaceuticals Inc. Mannose...

...was EVP of business operations and general counsel at Tokai Pharmaceuticals Inc. (NASDAQ:TKAI). Diagnostic play Navidea Biopharmaceuticals Inc....

...of the oral cavity, breast cancer or melanoma. It is also approved in the EU. Navidea Biopharmaceuticals Inc....

...Bind partnered non-exclusively with Navidea’s Macrophage Therapeutics subsidiary to develop tumor therapies that combine Bind’s Accurin...
...of disease mediated by MBR-positive macrophages and tumor-associated macrophages. Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Navidea Biopharmaceuticals Inc....

...Navidea will be eligible to receive a milestone payment upon FDA approval plus royalties. Navidea...
...detection of Parkinson’s disease (see BioCentury, Aug. 6, 2012). Alseres Pharmaceuticals Inc. (OTCQB:ALSE), Auburndale, Mass. Navidea Biopharmaceuticals Inc....

...Ohio Business: Diagnostic Date completed: 2015-05-11 Type: Debt financing Raised: $50 million Investor: CRG Note: Navidea...

...loan of up to $60 million from CRG, including an initial $50 million at closing. Navidea...
...for the first four years, and a 14% annual interest rate. WBB Securities LLC was Navidea's...